arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Nuo Therapeutics, Inc.

AURX
— Price unavailable
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
55 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Nuo Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap —
Dividend Yield —
Revenue Growth 152.6% ↘
Op. Margin -9.4% ↗
ROIC 8.6% ↘
FCF / Share $-0.01 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.77M
↑ +152.6% —
Net Income Profit after all expenses
$-618.47K
↑ +17.1% —
Operating Margin Operating profit as % of sales
-9.4%
↑ +72.5% 3th
FCF / Share Free cash flow per share
$-0.01
↑ +37.8% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
4
Returns ↑
100
Financial Health ↓
6
Cash Quality ↓
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 55 quarters